What is Owlo?
Owlo is building next-generation, AI-enhanced label-free 3D microscopy to provide non-invasive imaging solutions for healthcare applications like IVF and drug discovery.
Business and value proposition
Owlo is developing the next generation of label-free microscopy for healthcare, focusing on real-time, 3D imaging solutions to address unmet medical needs. Their technology provides non-invasive capabilities across various applications, including IVF and drug discovery. By integrating AI, OWLO enhances imaging diagnostics and offers innovative tools that improve outcomes for patients and professionals alike.
Why we invested?
Owlo combines top-tier scientific talent from Institut Langevin with a strong entrepreneurial track record and a unique real-time, label-free 3D imaging technology. This breakthrough enables non-invasive analysis of live biological samples, with promising applications in IVF, 3D cell models for drug discovery, and ophthalmology. The solution is modular and easily integrable, and the team has shown smart execution with limited resources. However, the project is still early, with clinical validation, regulatory approvals, and commercialization, especially in Europe, remaining key challenges. The absence of medical expertise and limited visibility on future funding add to the risk.
%20Florian%20Lehmann%2C%20Flavio%20Alario%2C%20Kenan%20Deniz.jpg)
